Published in Am J Med on December 01, 1995
Traumatic Hemarthrosis of the Knee Secondary to Hemophilia A in a Collegiate Soccer Player: A Case Report. J Athl Train (2002) 0.88
A Survey of Team Physicians on the Participation Status of Hemophilic Athletes in National Collegiate Athletic Association Division I Athletics. J Athl Train (2003) 0.78
Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature. Drug Des Devel Ther (2015) 0.75
Treatment of inherited coagulation disorders. Am J Med (1996) 0.75
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
Essential role of LAT in T cell development. Immunity (1999) 3.94
Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate. Lancet (1990) 2.91
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood (2001) 1.99
The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia (2003) 1.80
Acquired inhibitors. Baillieres Clin Haematol (1996) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
von Willebrand factor interacts with malignant hematopoietic cell lines: evidence for the presence of specific binding sites and modification of von Willebrand factor structure and function. J Lab Clin Med (1992) 1.54
PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost (1998) 1.48
Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med (1986) 1.32
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet (1988) 1.24
Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia (2011) 1.21
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia (2005) 1.18
Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia (2011) 1.17
Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study. Lancet (1994) 1.16
A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood (1995) 1.11
In vitro correlation of platelet aggregation with occurrence of disseminated intravascular coagulation and subacute bacterial endocarditis. J Lab Clin Med (1987) 1.10
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia (2015) 1.09
Acute pulmonary embolism treated with tissue plasminogen activator. Lancet (1986) 1.06
Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J Acquir Immune Defic Syndr (1999) 1.05
Microwave technology for the rapid thawing of frozen blood components. Am J Clin Pathol (1985) 1.00
Abnormal T-lymphocyte subpopulations associated with transfusion of blood-derived products. Lancet (1983) 0.96
Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA (1992) 0.95
Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia (2011) 0.94
Warfarin anticoagulation: difficulties in interpretation of the prothrombin time. Thromb Res (1982) 0.92
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia (2012) 0.91
Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia (2004) 0.90
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol (1992) 0.90
Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunction. Ann N Y Acad Sci (1984) 0.88
Cardiovascular comorbidities are increased in U.S. patients with haemophilia A: a retrospective database analysis. Haemophilia (2013) 0.88
D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolism. J Clin Pathol (2001) 0.88
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation (1990) 0.87
Methylene blue for neutralization of heparin. Thromb Res (1989) 0.86
Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation. Am J Hematol (1995) 0.85
Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol (1982) 0.85
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia (2008) 0.85
Hemostatic responses to maximal exercise in oral contraceptive users. Am J Obstet Gynecol (1999) 0.84
Stimulation of fibrinogen synthesis: a possible functional role of fibrinogen degradation products. Blood (1980) 0.84
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol (1996) 0.84
Inverse correlation between age related abnormalities of T-cell immunity and circulating thymosin alpha 1 levels in haemophilia A. Br J Haematol (1984) 0.84
Ultrastructural markers in circulating lymphocytes of subjects at risk for AIDS. Am J Clin Pathol (1985) 0.83
The effect of homologous thrombin and fibrinogen degradation products on fibrinogen synthesis in rabbits. J Lab Clin Med (1979) 0.83
Butaclamol hydrochloride (AY-23,028): an early evaluation in severely ill schizophrenics. Dis Nerv Syst (1975) 0.83
Total knee arthroplasty in human immunodeficiency virus-infected hemophiliacs. J Arthroplasty (1995) 0.82
ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective. Haemophilia (2014) 0.82
Carotid artery disease in vascular ocular syndromes. J Clin Neuroophthalmol (1993) 0.82
Distribution and correlates of plasma fibrinogen in middle-aged women. Initial findings of the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Arterioscler Thromb Vasc Biol (1995) 0.82
Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia (2001) 0.82
Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia (1999) 0.81
The challenge of pain evaluation in haemophilia: can pain evaluation and quantification be improved by using pain instruments from other clinical situations? Haemophilia (2012) 0.81
Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. Am J Hematol (1998) 0.80
Both atenolol and propranolol blunt the fibrinolytic response to exercise but not resting fibrinolytic potential. Am J Cardiol (2000) 0.80
Regulation of fibrinogen biosynthesis: effect of fibrin degradation products, low-molecular-weight peptides of fibrinogenolysis, and fibrinopeptides A and B. J Lab Clin Med (1979) 0.80
Thymosin in the staging and treatment of HTLV-III positive homosexuals and hemophiliacs with AIDS-related immune dysfunction. Adv Exp Med Biol (1985) 0.80
IgA inhibitor to factor VIII/von Willebrand factor. Br J Haematol (1985) 0.80
Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacs. J Infect Dis (1995) 0.79
Prophylaxis in real life scenarios. Haemophilia (2014) 0.79
von Willebrand factor: what is its role in the immune response in haemophilia? Haemophilia (2011) 0.79
Collagen-factor VIII/von Willebrand factor protein interaction. Blood (1984) 0.79
Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? J Thromb Haemost (2012) 0.78
Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation (1992) 0.78
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. J Thromb Haemost (2013) 0.78
Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII. Haemophilia (2002) 0.77
Managing chronic pain in adults with haemophilia: current status and call to action. Haemophilia (2014) 0.77
Stimulation of fibrinogen biosynthesis by fibrinogen fragments D and E. Br J Haematol (1983) 0.77
Risk of HIV infection and AIDS in women and girls with coagulation disorders. AIDS (1994) 0.76
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature. Haemophilia (2007) 0.76
Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost (2010) 0.76
Outcomes of mentored, grant-funded fellowship training in haemostasis /thrombosis: findings from a nested case-control survey study. Haemophilia (2011) 0.75
The National Hemophilia Foundation provides a model of a national blood monitoring system. Transfusion (1996) 0.75
Iatrogenic arsenic induced Mees' lines. Postgrad Med J (2006) 0.75
Parvovirus B19 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia. Am J Hematol (1997) 0.75
The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy. JAMA (1989) 0.75
Oral contraceptives and smoking, current considerations: recommendations of a consensus panel. Am J Obstet Gynecol (1999) 0.75
MASAC Consensus Conference: impediments to conducting clinical research in persons with haemophilia, von Willebrand's disease and rare bleeding disorders. Haemophilia (2012) 0.75
Assessment of antipsychotic activity of an unique agent: SU-23397. Psychopharmacol Commun (1975) 0.75
Acquired hemolytic anemia and thrombocytopenia (Evans' syndrome) in hemophilia. N Engl J Med (1983) 0.75
von Willebrand disease in the 21st century: current approaches and new challenges. Haemophilia (2009) 0.75
Tissue plasminogen activator and acute pulmonary embolism. J Cell Biochem (1988) 0.75
Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects. J Biol Response Mod (1986) 0.75
Coagulation factor IX: successful surgical experience with a purified factor IX concentrate. Am J Hematol (1992) 0.75
Fibrinolytic activity is similar in physically active men with and without a history of myocardial infarction. Arterioscler Thromb Vasc Biol (1997) 0.75
Viral safety and clotting factor concentrates. Thromb Haemost (1994) 0.75
Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator. Semin Thromb Hemost (1987) 0.75
Thrombolytic therapy of acute pulmonary embolism: current status and future potential. J Am Coll Cardiol (1987) 0.75
Biochemical and functional properties of protein C and protein S. Clin Chim Acta (1987) 0.75
Phenotypic and ultrastructural characterization of a medullary thymocyte acute lymphoblastic leukemia with cellular procoagulant activity. Cancer (1985) 0.75
Aortic plaque as a potential cause for cerebral ischemia. J Tongji Med Univ (1997) 0.75
Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A. Haemophilia (1999) 0.75
Treatment of silastic catheter-induced central vein septic thrombophlebitis. Am J Med Sci (1986) 0.75
[Comparison of current means of diagnosis and prognosis of renovascular hypertension. Apropos of 28 cases]. J Urol Nephrol (Paris) (1971) 0.75
Skin necrosis following prolonged administration of coumarin in a patient with inherited protein S deficiency. Am J Hematol (1991) 0.75
Increase in platelet support of thrombin generation after thrombolytic therapy. Am J Cardiol (1992) 0.75
Fibrinolytic activity is not dependent upon exercise mode in post-myocardial infarction patients. Eur J Appl Physiol Occup Physiol (1998) 0.75